Me-Too Cancer Drugs Not Often Compared to Original

The analysis of FDA-approved next-in-class drugs also found that, among RCTs with head-to-head trials, fewer than 1 in 4 of the me-too agents demonstrated a survival benefit.
Medscape Medical News

source https://www.medscape.com/viewarticle/me-too-cancer-drugs-not-often-compared-original-2025a1000kat?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension